Strides Pharma Sells Majority Stake in Pivot Path for ₹1,000 Million

Strides Pharma Science Limited's Board of Directors has approved a strategic investment by a consortium led by Ascent Capital and co-investor Vintage Classic in its subsidiary, Pivot Path Private Limited. The deal involves the sale of a majority stake in Pivot Path by Strides for an aggregate consideration of approximately ₹1,000 million, with an additional primary infusion of ₹500 million into Pivot Path by Ascent Capital to fund its growth. Following the transaction, Pivot Path will be reclassified as an Associate Company. The sale consideration will be paid in two tranches: ₹750 million at initial closing and ₹250 million on the first anniversary. The transaction is expected to be completed by June 30, 2026, for the share sale and by July 31, 2026, for the primary infusion.